Đang chuẩn bị liên kết để tải về tài liệu:
Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: A multicenter retrospective study

Although nivolumab (anti-programmed cell death-1 antibody) is a promising approach for advanced gastric cancer (AGC), the response rate remains limited. The aim of this multicenter retrospective study was to determine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC. | Sano et al. BMC Cancer 2022 22 22 https doi.org 10.1186 s12885-021-09118-3 RESEARCH ARTICLE Open Access Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer a multicenter retrospective study Akihiko Sano1 Makoto Sohda1 Nobuhiro Nakazawa1 Yasunari Ubukata1 Kengo Kuriyama1 Akiharu Kimura1 Norimichi Kogure1 Hisashi Hosaka2 Atsushi Naganuma3 Masanori Sekiguchi4 Kana Saito5 Kyoichi Ogata1 Makoto Sakai1 Hiroomi Ogawa1 Ken Shirabe1 and Hiroshi Saeki1 Abstract Background Although nivolumab anti-programmed cell death-1 antibody is a promising approach for advanced gastric cancer AGC the response rate remains limited. The aim of this multicenter retrospective study was to deter- mine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC. Methods Fifty-eight patients with AGC who were treated with nivolumab as a third or later line from October 2017 to December 2018 at any of five clinical sites were enrolled in the study. The correlation between the best over- all response and clinical features was investigated. Overall survival and progression-free survival after initiation of nivolumab were calculated and clinical features that could be predictors of the prognosis were sought. Results The disease control rate DCR for nivolumab was 36.2 and was significantly correlated with perfor- mance status p 0.021 metastasis to one organ p 0.006 and grade 2 or higher immune-related adverse events p 0.027 . There was also a significant association between response to nivolumab and ability to receive subsequent chemotherapy p 0.022 . In the analysis of overall survival the following variables were identified as being signifi- cantly associated with a poor outcome Eastern Cooperative Oncology Group performance status 1 prior treat- ment with trastuzumab no immune-related adverse events lack of a response to nivolumab and inability to receive subsequent .